# Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices

> **NCT07352228** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Xijing Hospital** · enrollment: 350 (estimated)

## Conditions studied

- Rebleeding of Portal Hypertension in Liver Cirrhosis
- Propranolol
- Carvedilol

## Interventions

- **DRUG:** Propranolol
- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT07352228
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-01-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07352228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07352228, "Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07352228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*